Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
RESEARCH TOOLSreports
VERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.31 - $15.55
Previous CloseN/A
Volume257.30K
Average Volume (3M)1.41M
Market Cap
$595.82M
Enterprise Value-$59.04M
Total Cash (Recent Filing)$172.56M
Total Debt (Recent Filing)$69.98M
Price to Earnings (P/E)―
Beta3.23
Next Earnings
May 07, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding88,795,770
10 Day Avg. Volume1,544,191
30 Day Avg. Volume1,413,124
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)30.95
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.83
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$21.43Price Target Upside219.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Verve Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityVERV ended with a strong cash position, providing financial stability into mid-2027.
Strategic PartnershipsLilly obtained opt-in rights to VERVE-102, allowing for a 50/50 cost/profit sharing of its commercialization in the US market, in exchange for funding 33% of worldwide development expenses.
Bears Say
Collaborations And PartnershipsDecision by VRTX to discontinue its collaboration with VERV in light of changing priorities.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.30 and its highest was $15.55 in the past 12 months.
What is Verve Therapeutics’s market cap?
Verve Therapeutics’s market cap is $595.82M.
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.675 by $0.095.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 88,795,770 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.675. Following the earnings report the stock price went down -1.743%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Currently, no hedge funds are holding shares in VERV
---
Verve Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (219.37% Upside)
$21.43 (219.37% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 69.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.08%
12-Months-Change
Fundamentals
Return on Equity
-36.36%
Trailing 12-Months
Asset Growth
-13.99%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Month Forecast
Average Price Target
$21.43
▲(219.37% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-34.93%
reiterated a buy rating 13 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -34.93% per trade.
---